The Global Fund to fight AIDS, Tuberculosis and Malaria (The Global Fund) is a global partnership of governments, civil society, technical agencies, the private sector and people affected by the three diseases.
The Global Fund has played a pivotal role in bringing down the number of HIV infections and AIDS-related deaths since it was created in 2002.
It mobilizes and pools resources to invest strategically in locally-led health programs in low- and middle-income countries. In total, the Global Fund has allocated more than 60 billion US dollars between 2002 and 2023 to respond to HIV, tuberculosis, malaria, and COVID-19 and to programs that strengthen systems for health across more than 120 countries.
On average, the Global Fund invests $4 billion US dollars annually in support of national and local programs. In 2021-2023, 72% of the funds globally were invested in sub-Saharan African countries.
"Since 2002, The Global Fund partnership has saved 59 million lives in more than 120 countries
The results
The Global Fund releases an annual Results Report highlighting the progress that has been made for each of the three diseases that the Global Fund targets, as well as progress made in strengthening health systems and pandemic preparedness.
In 2022, 24.5 million people living with HIV were on antiretroviral therapy in countries where the Global Fund invests. AIDS-related deaths have dropped by 72% since the partnership was launched 2002.
Of all international financing for HIV interventions in 2022, 28% came from the Global Fund, underlining the importance of the partnership for the global HIV and AIDS reponse.
The impact of COVID-19
The 2023 Results Report highlights how we are now starting to get back on track since the COVID-19 pandemic caused significant declines in HIV testing and prevention services, especially for key and vulnerable populations.
Compared with 2019, people reached by HIV prevention programs declined by 11% in 2020, while young people reached with prevention services declined by 12%. Mothers receiving medicine to prevent transmitting HIV to their babies dropped by 4.5%. HIV testing overall dropped by 22%.
To address the declines, the Global Fund supported initiatives in direct response to COVID-19 and initiatives aimed at mitigating the negative effects COVID-19 had on the responses to HIV, tuberculosis, and malaria
Results from 2022 include 8.1 million HIV tests taken by priority and key populations – compared to 5.5 million in 2020. This shows that testing programs are finally recovering – and accelerating progress – after COVID-19.
The investments in mitigating the effects of the pandemic continue to strengthen health systems and better prepare the world for the next pandemic.
AIDS-Fondet and The Global Fund
AIDS-Fondet works to increase awareness of the Global Fund – and the diseases it works to end.
AIDS-Fondet is leading advocacy for Nordic support of the Global Fund in collaboration with partners in Sweden and Norway.
The partnership aims at harnessing political support for the Global Fund in all three countries and to ensure continued and increased funding to the Global Fund.
Replenishment rounds
The Global Fund funding cycle starts and ends with the so-called replenishment rounds. A replenishment round is a fundraisning exercise that takes place every three years. 2019 was the start of the sixth replenishment cycle since 2005 (before which funding was ad-hoc contributions), covering the invesments made in the period 2020-2022.
At the most recent, seventh replenishment round in 2022, the Global Fund raised a record breaking 15.7 billion US dollars covering the 2023-2025 replenishment period. This includes 517.5 million US dollars mobilized in pledges from Scandinavia.